Clinical Trial

Prostatic Size Reduction Following of Leuprorelin Acetate

Study acronym: PROSTSIZE
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated December 15, 2024 completion). Its status may not reflect the trial's current state.
Summary
To determine the possible reduction in prostate size following the administration of Leuprelin prior to the application of radiotherapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-12-27; most recent amendment 2024-09-09.
Status change: Not Yet Recruiting → Recruiting 2024-05-14
Trial Details
NCT Number NCT06184464
Lead Sponsor Consorci Sanitari de Terrassa
Conditions Prostate Cancer Adenocarcinoma, Prostate Adenocarcinoma
Enrollment 40 participants
Start Date 2024-02-02
Primary Completion 2024-12-15 (estimated)
Study Completion 2024-12-15 (estimated)
Updated on ClinicalTrials.gov 2024-09-19